Clinical trials update from the joint European Society and World Congress of Cardiology meeting: PEP-CHF, ACCLAIM and the HHH study.
This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the joint European Society and World Congress of Cardiology meeting held in Barcelona in September 2006. All reports should be considered as preliminary data, as analyses may change in the final publication. The PEP-CHF study suggests that perindopril improves symptoms and functional capacity and may reduce heart failure hospitalisations in patients with diastolic heart failure. Although immune modulation therapy failed to reduce the incidence of all-cause mortality and cardiovascular hospitalisations in the ACCLAIM study, the observed differences in outcome in some heart failure patients warrants further investigation. The HHH study failed to show a beneficial effect of telemonitoring over usual care in patients with heart failure but potentially important country interactions were observed.
Cleland
John G F
JG
Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston-upon-Hull, HU15 5JQ, UK. a.p.coletta@hull.ac.uk
Coletta
Alison P
AP
Clark
Andrew L
AL
D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002303:Cardiac Output, Low / Q000188:drug therapy* / Q000276:immunology; D002309:Cardiology; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D005060:Europe; D019317:Evidence-Based Medicine; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D020913:Perindopril / Q000627:therapeutic use*; D012955:Societies, Medical; D017216:Telemedicine; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D007155:Immunologic Factors; D020913:Perindopril